Who is sponsoring NCT03603756?

NCT03603756 is sponsored by Chinese Academy of Medical Sciences.

What condition does NCT03603756 study?

NCT03603756 studies Esophageal Squamous Cell Carcinoma.

What drugs are being tested in NCT03603756?

Interventions: SHR-1210, Apatinib, Irinotecan Injection, Paclitaxel liposome, Nedaplatin.

What is the status of NCT03603756?

NCT03603756 is currently UNKNOWN.

Last reviewed 2020-02-11 · How we verify

SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer

NCT03603756 PHASE2 UNKNOWN

Patients with previously untreated advanced or metastatic esophageal squamous cell carcinoma are recruited to this prospective non-randomized study comprising two separate cohorts. Patients will receive SHR-1210, a novel anti-PD-1 antibody, with apatinib and either irinotecan or paclitaxel liposome plus nedaplatin. The primary endpoint is to determine the objective response rate (ORR) of patients in both cohorts. The regimen(s) of promising efficacy will be further verified in subsequent randomized studies to define the optimal combination of immunotherapy, anti-angiogenesis and chemotherapy in advanced esophageal cancer patients.

Details

Lead sponsor	Chinese Academy of Medical Sciences
Phase	PHASE2
Status	UNKNOWN
Enrolment	45
Start date	Tue Jul 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Mar 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

SHR-1210
Apatinib
Irinotecan Injection
Paclitaxel liposome
Nedaplatin

Countries

China